Welcome Dr. Shayna Sarosiek!
We are pleased to announce the addition of Dr. Shayna Sarosiek to the Bing Center for Waldenstrom's Macroglobulinemia.
Prior to joining the Bing Center, Dr. Sarosiek completed her Internal Medicine residency, as well as her Amyloidosis and Hematology/Oncology Fellowship at Boston University Medical Center. After completing her training she remained as a faculty member at Boston University for 4 years. During that time she worked as a hematologist treating patients with benign and malignant hematologic issues, such as monoclonal gammopathy of undetermined significance (MGUS), lymphoma, WM, and multiple myeloma. She focused the majority of her research efforts on plasma cell disorders, including MGUS, multiple myeloma and amyloidosis. She also actively participated in the care of patients at the Boston University Amyloidosis Center and has published many original research articles in that field. She is looking forward to using the expertise she gained at that center to improve the care of patients with WM and AL amyloidosis.
In the Bing Center Dr. Sarosiek will be joining Dr. Jorge Castillo in the clinic to see patients and help care for the constantly increasing number of Waldenstrom patients at our center. She will also be actively involved in clinical research and will focus her research efforts on the use of immunotherapies and antibody treatments in WM, as well as developing therapies and caring for those patients who have both WM and AL amyloidosis.
Please join us in welcoming Dr. Sarosiek to the Bing Center!
Waldenstrom's Macroglobulinemia Clinic
The Waldenstrom's Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Basic Research
Waldenström’s macroglobulinemia (WM) is a distinct B-cell malignancythat results from the accumulation, predominantly in the bone marrow, of clonally related B type lymphocytes, lymphoplasmacytic cells and plasma cells which secrete a monoclonal IgM protein.1 This condition is considered to correspond to the lymphoplasmacytic lymphoma (LPL) as defined by the World Health Organization classification system.2 Most cases of LPL are WM, with less than 5% of cases made up of IgA, IgG and non-secreting LPL ...
Latest Bing Center News
Clinical Trials Are Moving Out of the Lab and Into Peopleʼs Homes
After the pandemic forced thousands of trials to shut down, researchers found clever ways to conduct human studies remotely — while reaching more people, quickly and cheaply.
Current and Future Treatments for Waldenstrom Macroglobulinemia
What are the treatments for Waldenstrom macroglobulinemia and what's in the pipeline? Can Waldenstrom patients plan for a higher quality of life? Dr. Jorge Castillo, Clinical Director, Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, presents an overview of his presentation at the 2020 IWMF with Patient Power co-founder Andrew Schorr.
Progress in the Treatment of Waldenstrom’s Macroglobulinemia (Webcast)
Workshop Date and Time: Wednesday, April 21, 2021, 12:30 – 1:30 pm, Eastern Time. Registrants can listen in live over the phone or online as a webcast.
Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Despina Fotiou and Meletios A. Dimopoulos present a summary of trial findings and details regarding various BTK inhibitors, including ibrutinib, zanubrutinib, acalabrutinib, tirabrutinib, LOXO-305, etc.
BeiGene (BGNE) Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA in Waldenstrom's Macroglobulinemia
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for BRUKINSA® (zanubrutinib) for the treatment of adult patients with Waldenström’s Macroglobulinemia (WM). The Prescription Drug User Fee Act (PDUFA) target action date is October 18, 2021.
Podcast with Dr. Jorge Castillo: MGUS, Myeloma, WM AND Immunology, Oh My!
December 21, 2020: Dr. Jorge Castillo walks us through immunology basics, teaches us the limitations of the SPEP, plus some additional tests that complement it (think Immunofixation), shares his clinical gestalt about when to suspect MGUS, Myeloma, Waldenstrom’s, and Amyloidosis–and finally, how to talk to patients about them.
International Myeloma Society Recommendations for Covid-19 vaccinations in patients with MM and related conditions
Dear IMS Member: We hope you are well during these difficult times. As a response to the current pandemic, the International Myeloma Society has developed the following Recommendations for anti-Covid-19 vaccination in patients with multiple myeloma (MM) and related conditions, AL amyloidosis and other monoclonal gammopathies of clinical significance.
Cancer and the COVID-19 Vaccine
On January 27, Dana Farber held a webinar to review the information regarding COVID-19 vaccinations for patients. Catherine Flynn (from the Bing Center Clinic) shares the following highlights from the webinar. Note, the entire webinar was recorded and posted to Facebook, using the following link:
COVID-19 Facts and Resources
Based on the latest guidance we have received from the state of Massachusetts, we expect Dana-Farber's supply of COVID-19 vaccine for patients to be very limited in February and perhaps longer. We are working hard to place special focus on getting vaccines to our most at-risk patients, in compliance with the state's rollout guidelines, as we receive allotments of the vaccine.
Advances in Multiple Myeloma and Waldenstrom’s Macroglobulinemia including COVID-19 Update
Please join the Center for Multiple Myeloma for a free webinar for patients and families to learn about the most recent updates in muliple myeloma and Waldenstrom's macroglobulinemia including the impact of COVID-19 and vaccination.